June 2013
Volume 54, Issue 15
ARVO Annual Meeting Abstract  |   June 2013
Ranibizumab for the treatment of diabetic macular edema in patients treated with Bevacizumab
Author Affiliations & Notes
  • Gisela Velez
    Ophthalmology, Univ of Massachusetts Med School, Worcester, MA
    Central Massachusetts Retina and Uveitis Center, Worcester, MA
  • Footnotes
    Commercial Relationships Gisela Velez, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 2395. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Gisela Velez; Ranibizumab for the treatment of diabetic macular edema in patients treated with Bevacizumab. Invest. Ophthalmol. Vis. Sci. 2013;54(15):2395.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: Anti-VEGF agents have been shown to be effective in the treament and management of diabetic maculat edema. The CATT study has shown that Ranibizumab (Lucentis) and Bevacizumab (Avastin), are similarly effective for the treatment of exudative macular degeneration. The purpose of our study is to determine whether or not there is an advantage to the use of Ranibizumab over Bevacizumab; in the management and treatment of diabetic macular edema.

Methods: The records of all patients treated with anti-VEGF agents for diabetic macular edema were reviewed. 25 eyes (of 16 patients) were identified which had been treated first with Bevacizumab (1.25 mg), then switched to Ranibizumab (0.3 mg). Visual acuity was measurred by Snellen chart and retinal thickness was measured using Cirrus OCT. All eyes were treated at monthly intervals.

Results: All eyes treated with Bevacizumab showed an improvement in visual acuity, with a reduction in retinal thickening on OCT. On average, each eye received a total of 8 intravitreal Bevacizumab injections before switching to Ranibizumab. All of the eyes had persistent thickening on OCT after treatment with Bevacizumab. After Bevacizumab, each eye received an average of 6 Ranibizumab treatments. Although Ranibizumab injections did not result in a significant improvement in VA, there was an observed decrease in retinal thickness as measured by OCT, in patients switched from Bevacizumab to Ranibizumab.

Conclusions: Although Ranibizumab can result in better anatomical results, Bevacizumab is equally effective and results in VA improvement. Bevacizumab is therefore a viable alternative to Ranibizumab for the treatment of diabetic macular edema.

Keywords: 499 diabetic retinopathy • 505 edema • 688 retina  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.